Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026
Go back to Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 49.91 +0.27 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $49.64 | 52 Week High | $0.52 | |||
| Open | $49.98 | 52 Week Low | $0.08 | |||
| Day High | $51.75 | P/E | N/A | |||
| Day Low | $49.62 | EPS | $-3.80 | |||
| Volume | 5,066,145 | |||||
